Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient.
Fusarium infection is known to cause major morbidity and mortality in immunocompromised hosts. We report the successful treatment of disseminated Fusarium infection with skin manifestations in a severely neutropenic, immunocompromised host with voriconazole, a new second-generation triazole. Voriconazole might be an alternative therapy for patients with neutropenia who have fusariosis that is refractory or unresponsive to amphotericin B or its liposomal formulation.
Consigny
Sophie
S
Department of Internal Medicine, Hospital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.
Dhedin
Nathalie
N
Datry
Annick
A
Choquet
Sylvain
S
Leblond
Véronique
V
Chosidow
Olivier
O
D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D005670:Fusarium / Q000187:drug effects; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D009181:Mycoses / Q000188:drug therapy* / Q000503:physiopathology / Q000635:transmission; D009503:Neutropenia / Q000209:etiology; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D000666:Amphotericin B; D065819:Voriconazole